Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy
Collection of Safety, Efficacy and Resource Utilization Information in Patients Who Have Received Melphalan PHP With the Delcath Hepatic Delivery System for the Treatment of Unresectable Hepatic Malignancy
Sponsor: Delcath Systems Inc.
Listed as NCT03266042, this observational or N/A phase trial focuses on Hepatic Malignant Neoplasm Primary Non-Resectable and remains ongoing. Sponsored by Delcath Systems Inc., it has been updated 8 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status
-
Oct 2020 — Jan 2021 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Oct 2018 — Oct 2020 [monthly]
Recruiting
▶ Show 3 earlier versions
-
Jun 2018 — Oct 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Sep 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Delcath Systems Inc.
For direct contact, visit the study record on ClinicalTrials.gov .